doi: 10.1161/hy0202.102837
(Hypertension. 2002;39:412.)
© 2002 American Heart Association, Inc.
Scientific Contributions |
Methoxyestradiols Mediate the Antimitogenic Effects of Locally Applied Estradiol on Cardiac Fibroblast Growth
From the Department of Obstetrics and Gynecology, Clinic for Endocrinology, University Hospital Zurich (R.K.D., M.R., B.I.), Switzerland; Center for Clinical Pharmacology, Department of Medicine (R.K.D., D.G.G., L.C.Z., E.K.J.), and Department of Pharmacology (L.C.Z., E.K.J.), University of Pittsburgh Medical Center, Pa.
Correspondence to Dr Raghvendra K. Dubey, Department of Obstetrics and Gynecology, Clinic for Endocrinology, D217, NORD-1, Frauenklinik, University Hospital Zurich, CH-8091 Zurich, Switzerland. E-mail rag{at}fhk.usz.ch
Estradiol inhibits cardiac fibroblast growth and may protect against cardiac remodeling associated with heart disease. However, the mechanisms by which estradiol attenuates cardiac fibroblast growth remain unclear. Because cardiac fibroblasts express cytochrome P450s (CYP450s) and catechol-O-methyltransferase (COMT) capable of converting estradiol to hydroxyestradiols and methoxyestradiols, respectively, and because hydroxyestradiols and methoxyestradiols (estradiol metabolites with little affinity for estrogen receptors) are potent inhibitors of cardiac fibroblast growth, we hypothesized that the antimitogenic effects of estradiol are mediated via hydroxyestradiols and/or methoxyestradiols. The inhibitory effects of estradiol (1 to 100 nmol/L) on serum-stimulated 3H-thymidine incorporation (DNA synthesis), 3H-proline incorporation (collagen synthesis), and cell number (proliferation) were enhanced (P<0.005) by CYP450 inducers 3-methylcholanthrene (10 µmol/L) and phenobarbital (10 µmol/L). Moreover, the inhibitory effects of estradiol were blocked by the CYP450 inhibitor 1-aminobenzotriazole (10 µmol/L) and the COMT inhibitors quercetin (10 µmol/L) and OR486 (10 µmol/L). In contrast to estradiol, the modulators of CYP450 and COMT were poor ligands for estrogen receptors (binding affinity 
0.0001% versus estradiol). In cardiac fibroblasts, both quercetin and OR486 inhibited the metabolism of hydroxyestradiol to methoxyestradiol and blocked the inhibitory effects of hydroxyestradiol on cardiac fibroblast proliferation and DNA and collagen synthesis. The abrogating effects of quercetin and OR486 on the metabolism and antimitogenic effects of 2-hydroxyestradiol were mimicked by 20 µmol/L norepinephrine and isoproterenol, substrates for COMT. Our findings provide evidence that estradiol can inhibit cardiac fibroblast growth via an estrogen receptor–independent pathway that involves the local metabolism of estradiol to methoxyestradiols.
Key Words: hormones • menopause • fibroblasts • metabolism • cardiovascular diseases
This article has been cited by other articles:
 |
|
 |
|
  C. M. Masi, L. C. Hawkley, J. D. Berry, and J. T. Cacioppo Estrogen Metabolites and Systolic Blood Pressure in a Population-Based Sample of Postmenopausal Women J. Clin. Endocrinol. Metab., March 1, 2006; 91(3): 1015 - 1020. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. F. Reckelhoff Sex Steroids, Cardiovascular Disease, and Hypertension: Unanswered Questions and Some Speculations Hypertension, February 1, 2005; 45(2): 170 - 174. [Full Text] [PDF]
|
|
|
|
|
|
R. K. Dubey, E. K. Jackson, D. G. Gillespie, M. Rosselli, F. Barchiesi, A. Krust, H. Keller, L. C. Zacharia, and B. Imthurn Cytochromes 1A1/1B1- and Catechol-O-Methyltransferase-Derived Metabolites Mediate Estradiol-Induced Antimitogenesis in Human Cardiac Fibroblast J. Clin. Endocrinol. Metab., January 1, 2005; 90(1): 247 - 255. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. K. Dubey, B. Imthurn, L. C. Zacharia, and E. K. Jackson Hormone Replacement Therapy and Cardiovascular Disease: What Went Wrong and Where Do We Go From Here? Hypertension, December 1, 2004; 44(6): 789 - 795. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. K. Dubey, E. K. Jackson, D. G. Gillespie, L. C. Zacharia, and B. Imthurn Catecholamines Block the Antimitogenic Effect of Estradiol on Human Coronary Artery Smooth Muscle Cells J. Clin. Endocrinol. Metab., August 1, 2004; 89(8): 3922 - 3931. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. C. Zacharia, C. A. Piche, R. M. Fielding, K. M. Holland, S. D. Allison, R. K. Dubey, and E. K. Jackson 2-Hydroxyestradiol Is a Prodrug of 2-Methoxyestradiol J. Pharmacol. Exp. Ther., June 1, 2004; 309(3): 1093 - 1097. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.-L. Gross, M. Adamczak, T. Rabe, N. A. Harbi, J. Krtil, A. Koch, P. Hamar, K. Amann, and E. Ritz Beneficial Effects of Estrogens on Indices of Renal Damage in Uninephrectomized SHRsp Rats J. Am. Soc. Nephrol., February 1, 2004; 15(2): 348 - 358. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. K. Dubey, S. P. Tofovic, and E. K. Jackson Cardiovascular Pharmacology of Estradiol Metabolites J. Pharmacol. Exp. Ther., February 1, 2004; 308(2): 403 - 409. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. C. Zacharia, J. A. Gogos, M. Karayiorgou, E. K. Jackson, D. G. Gillespie, F. Barchiesi, and R. K. Dubey Methoxyestradiols Mediate the Antimitogenic Effects of 17{beta}-Estradiol: Direct Evidence From Catechol-O-Methyltransferase-Knockout Mice Circulation, December 16, 2003; 108(24): 2974 - 2978. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Otsuki, H. Gao, K. Dahlman-Wright, C. Ohlsson, N. Eguchi, Y. Urade, and J.-A. Gustafsson Specific Regulation of Lipocalin-Type Prostaglandin D Synthase in Mouse Heart by Estrogen Receptor {beta} Mol. Endocrinol., September 1, 2003; 17(9): 1844 - 1855. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. K. Dubey, L. C. Zacharia, D. G. Gillespie, B. Imthurn, and E. K. Jackson Catecholamines Block the Antimitogenic Effect of Estradiol on Human Glomerular Mesangial Cells Hypertension, September 1, 2003; 42(3): 349 - 355. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. C. Zacharia, R. K. Dubey, Z. Mi, and E. K. Jackson Methylation of 2-Hydroxyestradiol in Isolated Organs Hypertension, July 1, 2003; 42(1): 82 - 87. [Abstract] [Full Text] [PDF]
|
|